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Summary
Background Loss of cortical grey matter is a diagnostic marker of many neurodegenerative diseases, and is a key 
mediator of cognitive impairment. We postulated that cerebral amyloid angiopathy (CAA), characterised by cortical 
vascular amyloid deposits, is associated with cortical tissue loss independent of parenchymal Alzheimer’s disease 
pathology. We tested this hypothesis in patients with hereditary cerebral haemorrhage with amyloidosis–Dutch type 
(HCHWA-D), a monogenetic disease with minimal or no concomitant Alzheimer’s disease pathology, as well as in 
patients with sporadic CAA and healthy and Alzheimer’s disease controls.
Methods In this observational case-control study, we included six groups of participants: patients diagnosed with 
HCHWA-D using genetic testing; healthy controls age-matched to the HCHWA-D group; patients with probable 
sporadic CAA without dementia; two independent cohorts of healthy controls age-matched to the CAA group; and 
patients with Alzheimer’s disease age-matched to the CAA group. De-identiﬁ ed (but unmasked) demographic, 
clinical, radiological, and genetic data were collected at Massachusetts General Hospital (Boston, MA, USA), at Leiden 
University (Leiden, Netherlands), and at sites contributing to Alzheimer’s Disease Neuroimaging Initiative (ADNI). 
The primary outcome measure was cortical thickness. The correlations between cortical thickness and structural 
lesions, and blood-oxygen-level-dependent time-to-peak (BOLD-TTP; a physiological measure of vascular dysfunction) 
were analysed to understand the potential mechanistic link between vascular amyloid and cortical thickness. The 
radiological variables of interest were quantiﬁ ed using previously validated computer-assisted tools, and all results 
were visually reviewed to ensure their accuracy.
Results Between March 15, 2006, and Dec 1, 2014, we recruited 369 individuals (26 patients with HCHWA-D and 28 age-
matched, healthy controls; 63 patients with sporadic CAA without dementia; two healthy control cohorts with 63 and 
126 individuals; and 63 patients with Alzheimer’s disease). The 26 patients with HCHWA-D had thinner cortices 
(2·31 mm [SD 0·18]) than the 28 healthy controls (mean diﬀ erence –0·112 mm, 95% CI –0·190 to –0·034, p=0·006). The 
63 patients with sporadic CAA without dementia had thinner cortices (2·17 mm [SD 0·11]) than the two healthy control 
cohorts (n=63, mean diﬀ erence –0·14 mm, 95% CI –0·17 to –0·10, p<0·0001; and n=126, –0·10, –0·13 to –0·06, 
p<0·0001). All diﬀ erences remained independent in multivariable analyses. The 63 patients with Alzheimer’s disease 
displayed more severe atrophy than the patients with sporadic CAA (2·1 mm [SD 0·14], diﬀ erence 0·07 mm, 95% CI 
0·11 to 0·02, p=0·005). We found strong associations between cortical thickness and vascular dysfunction in the patients 
with HCHWA-D (ρ=–0·58, p=0·003) or sporadic CAA (r=–0·4, p=0·015), but not in controls. Vascular dysfunction was 
identiﬁ ed as a mediator of the eﬀ ect of hereditary CAA on cortical atrophy, accounting for 63% of the total eﬀ ect.
Interpretation The appearance of cortical thinning in patients with HCHWA-D indicates that vascular amyloid is an 
independent contributor to cortical atrophy. These results were reproduced in patients with the more common 
sporadic CAA. Our ﬁ ndings also suggest that CAA-related cortical atrophy is at least partly mediated by vascular 
dysfunction. Our results also support the view that small vessel diseases such as CAA can cause cortical atrophy even 
in the absence of Alzheimer’s disease, a conclusion that can help radiologists, neurologists, and other clinicians who 
diagnose these common geriatric conditions.
Funding National Institutes of Health.
Introduction
Loss of cortical grey matter is a marker of many 
neurodegenerative diseases, such as Alzheimer’s disease, 
and is a key mediator of associated cognitive impair-
ment.1,2 Cortical atrophy has also been observed in 
cerebral small vessel disease, a disorder generally 
recognised as a cause of subcortical white matter injury.3,4 
However, whether this observed atrophy in small vessel 
disease represents true loss of cortical grey matter, or 
simply results from the widening of cortical sulci due to 
loss of the underlying subcortical white matter, is 
unknown.5 It is important to understand the speciﬁ c 
contributors to cortical atrophy to test targeted 
therapeutic approaches.
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Cerebral amyloid angiopathy (CAA) is characterised by 
the gradual deposition of amyloid β (Aβ) peptides in the 
media and adventitia of small leptomeningeal and 
cortical vessels.6 CAA pathology has been identiﬁ ed as a 
major cause of lobar intracerebral haemorrhage, 
microbleeds, and superﬁ cial siderosis.7,8 In recent years, 
ﬁ ndings from multiple studies have shown that CAA 
also causes ischaemic subcortical tissue injury, an eﬀ ect 
probably mediated by vascular dysfunction.9–12 As a result 
of such ischaemic damage, CAA pathology has emerged 
as an independent contributor to age-related cognitive 
decline, even in patients who have not had symptomatic 
intracerebral haemorrhage.13,14
Although CAA—a cortical vascular pathology—has 
been linked to many subcortical lesions, its association 
with cortical structural changes has not been studied. 
The most important impediment for such a study is the 
frequent coexistence of CAA and parenchymal 
Alzheimer’s disease pathologies, making it diﬃ  cult to 
tease out the independent eﬀ ects of vascular amyloid on 
cerebral cortex. To overcome such confounding by 
parenchymal Alzheimer’s disease, we analysed a unique 
cohort of patients with hereditary cerebral haemorrhage 
with amyloidosis–Dutch type (HCHWA-D), a condition 
characterised by severe CAA pathology with minimal 
or no neuroﬁ brillary pathology.15 To assess the 
generalisability of ﬁ ndings from this select cohort, we 
further compared cortical thickness in patients with the 
more common sporadic CAA with age-matched healthy 
controls and individuals with Alzheimer’s disease. We 
also examined the correlation between cortical thickness 
and markers of structural cerebral injury (lobar 
microbleeds and leukoaraiosis) to understand whether 
these widespread lesions might aﬀ ect cortical loss or its 
measurement. Finally, we analysed the relationship 
between cortical thickness and a functional MRI (fMRI) 
marker of vascular reactivity to explore the possibility 
that CAA-related vascular dysfunction mediates cortical 
damage.
Methods
Study design and participants
This case-control study was done between March 15, 2006, 
and Dec 1, 2014, at two tertiary referral centres: Leiden 
University in the Netherlands, and Massachusetts General 
Hospital in Boston, MA, USA. The cohort of patients with 
HCHWA-D and their age-matched healthy controls were 
enrolled at the Leiden University Medical Center, Leiden, 
Netherlands.16 Controls were recruited from the spouses, 
extended family members, and friends of patients with 
Research in context
Evidence before this study
We searched PubMed for articles on cerebral amyloid 
angiopathy (CAA) and cortical atrophy published between 
Jan 1, 1990, and Nov 1, 2015, with diﬀ erent combinations of 
the terms “cerebral amyloid angiopathy”, “cortical atrophy”, 
“cortical thickness”, and ”cortical damage”, using no language 
restrictions. We did not ﬁ nd any reports addressing the 
association between CAA and cortical atrophy. We then 
repeated PubMed searches within the same time interval using 
combinations of the term “cerebral amyloid angiopathy” and 
each one of the following terms: “leukoaraiosis”, “white 
matter”, “structural networks”, and “subcortical injury”. We 
found several articles establishing associations between CAA 
and subcortical tissue damage, but the association of CAA and 
cortical atrophy was unknown. A major obstacle in clarifying 
the association between CAA and cortical atrophy has been the 
relatively common presence of parenchymal Alzheimer’s 
disease pathology in these patients, which is a well-established 
cause of cortical atrophy.
Added value of this study
This study shows that patients with hereditary cerebral 
haemorrhage with amyloidosis–Dutch type, a monogenetic 
disease with little or no concomitant parenchymal Alzheimer’s 
disease pathology, have decreased cortical thickness when 
compared to age-matched healthy controls. These ﬁ ndings 
were conﬁ rmed by comparing a well-deﬁ ned cohort of elderly 
patients with sporadic CAA to age-matched healthy controls. 
Mediation analyses also showed that vascular dysfunction 
explained at least part of the eﬀ ect of CAA pathology on cortical 
atrophy.
Implications of all the available evidence
Autopsy and imaging studies show that vascular amyloid 
pathology and lobar microbleeds, the hallmarks of CAA, are 
common ﬁ ndings in otherwise healthy old adults and patients 
with mild cognitive impairment. Multiple lines of evidence 
suggest that CAA pathology is an important contributor to 
subcortical tissue injury through vascular dysfunction and 
ischaemia. Cerebral amyloid angiopathy is also a 
well-established contributor to cognitive impairment in elderly 
patients, independent of intracerebral haemorrhages and other 
clinical consequences of vascular amyloid deposition. Our study 
is the ﬁ rst to suggest that CAA pathology might cause cortical 
atrophy, an eﬀ ect that might at least partly be mediated by 
vascular dysfunction. These new ﬁ ndings are important to 
understand the mechanisms of cerebral damage in patients with 
CAA, because these mechanisms can potentially have disabling 
clinical eﬀ ects and even confound therapeutic eﬀ orts. For 
example, some of the immunotherapies studied for Alzheimer’s 
disease (eg, bapineuzumab and gantenerumab) resulted in 
superﬁ cial cerebral microbleeds typical of CAA pathology, and 
accelerated atrophy has been reported in several antibody trials. 
On the basis of all available evidence, CAA pathology will need 
to be taken into consideration in future clinical trials for patients 
with Alzheimer’s disease or cognitive impairment. 
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HCHWA-D; all control individuals underwent genetic 
testing to rule out HCHWA-D. The diagnosis of 
HCHWA-D was based on DNA analysis for conﬁ rmation 
of the codon 693 mutation in the amyloid-β precursor 
protein gene APP.17 A total of 26 DNA-proven HCHWA-D 
mutation carriers and 28 age-matched (to within 5 years) 
controls were enrolled and demographics, vascular risk 
factors, and clinical features recorded.16 The healthy 
controls from the same communities in Leiden all had 
genetic testing to rule out HCHWA-D. Individuals with 
sporadic CAA were enrolled in an ongoing longitudinal 
cohort study of CAA at Massachusetts General Hospital. 
Detailed information including demographics, vascular 
risk factors, and clinical characteristics were recorded at 
the time of enrolment by AA and SvRf.9,11 None of the 
individuals with CAA had dementia and all were free of 
symptoms suggestive of new stroke for 6 months before 
MRI acquisition. All individuals with sporadic CAA had a 
diagnosis of probable CAA according to the pathologically 
validated Boston criteria.18
Patients with sporadic CAA were compared with two 
groups of age-matched healthy controls with com-
plementary strengths: controls in the Harvard Aging 
Brain (HAB) study,19 drawn from the same population as 
the CAA group but imaged on a diﬀ erent scanner type; 
and a second control group from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database,20 imaged using 
the same scanner type and strength as the CAA group. As 
a positive control group to demonstrate cortical atrophy, 
we also selected age-matched individuals with 
Alzheimer’s disease from the ADNI database. Age 
matching was done based on the closest age to the ﬁ rst 
decimal for age, from the available HAB cohort as well as 
ADNI healthy control and Alzheimer’s disease cohorts. 
Matching was performed without knowledge of 
radiological or other individual characteristics. Patient 
enrolment and data collection for these large studies have 
been extensively described.19,20 Speciﬁ cally, part of the data 
used in the preparation of this Article were obtained from 
the ADNI database. The primary goal of ADNI has been 
to test whether serial MRI, PET, other biological markers, 
and clinical and neuro psychological assessment can be 
combined to measure the progression of mild cognitive 
impairment and early Alzheimer’s disease.
Overall, 63 patients without dementia but with probable 
sporadic CAA were age-matched to 63 healthy controls 
from the ADNI database, 126 healthy controls from the 
HAB study, and 63 patients with Alzheimer’s disease 
from ADNI. The institutional review boards of the 
participating sites have approved this study. All 
participants completed written informed consent.
MRI acquisition
All patients with HCHWA-D and their respective controls 
had the same structural and fMRI sequences obtained in a 
General Electric 3 T scanner. Fluid-attenuated inversion 
recovery images (repetition time [TR] 11·0 s, echo time 
[TE] 125 ms, ﬂ ip angle 90°, slices 25, ﬁ eld of view [FOV] 
252 × 179·76 × 250 mm), three-dimensional T1-weighted 
images (TR 9 ms, TE 4·6 ms, ﬂ ip angle 8°, FOV 
224 × 177 × 168 mm), and susceptibility-weighted images 
(TR 45 ms, TE 31 ms, ﬂ ip angle 13°, FOV 250 × 175 × 112 mm) 
were obtained. All patients with sporadic CAA underwent 
structural MRI using a Siemens Avanto 1·5 T scanner 
(12-channel head coil), and 37 of them consecutively 
underwent fMRI after this protocol was implemented. 
Speciﬁ cally, T1-weighted (multi-echo magnetisation-
prepared rapid gradient-echo [MPRAGE]; 1 × 1 × 1 mm 
voxel size), high-resolution susceptibility-weighted 
imaging (0·75 × 0·75 × 1·30 mm voxel size), and ﬂ uid-
attenuated inversion recovery (1 × 1 × 1 mm voxel size) 
scans were acquired.11 The blood-oxygen-level-dependent 
(BOLD) fMRI protocol, using a block design with a visual 
stimulus, has been previously described.9 The individuals 
from the ADNI database underwent similar structural 
MRI sequences using Siemens 1·5 T scanners at several 
sites, whereas the healthy controls from the HAB study 
underwent MRI using a Siemens TrioTim 3 T scanner 
(12-channel head coil) within the same research facility as 
the sporadic CAA cohort.19,20 Extensive details of MRI 
acquisition parameters for these studies have been 
presented in previous publications.9,11,19,20
Cohort recruited in the Netherlands Cohort recruited in the USA
Patients with 
HCHWA-D (n=26)
Healthy controls 
(n=28)*
Patients with 
sporadic CAA (n=63)
ADNI healthy 
controls (n=63)†
HAB healthy 
controls (n=126)†
ADNI patients with 
Alzheimer’s disease (n=63)‡
Age, years 45·8 (13·9) 47·5 (11·8) 72·2 (5·4) 72·3 (4·6) 72·4 (5·3) 72·2 (5·4)
Sex
Men 10 (38%) 11 (39%) 49 (78%) 36 (57%) 72 (57%) 43 (68%)
Women 16 (62%) 17 (61%) 14 (22%) 27 (43%) 54 (43%) 20 (32%)
Previous intracerebral 
haemorrhage
15 (58%) 0 31 (49%) 0 0 0
Data are mean (SD) or n (%). CAA=cerebral amyloid angiopathy. ADNI=Alzheimer’s Disease Neuroimaging Initiative. HCHWA-D=hereditary cerebral haemorrhage with 
amyloidosis–Dutch type.  *Healthy controls matched to the patients with HCHWA-D. †Healthy controls matched to the patients with sporadic CAA. ‡Patients with Alzheimer’s 
disease matched to the patients with sporadic CAA. 
Table 1: Characteristics of participants at baseline
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Image processing
Three-dimensional cortical surface reconstruction was 
done with the FreeSurfer software suite (version 5.3).21–23 
The average cortical thickness of each hemisphere was 
calculated from representations of the grey–white and 
pial surfaces by taking into account the spatial and 
intensity singularities of the examined three-dimensional 
MPRAGE volume.24 This pipeline allowed the 
measurement of cortical thickness to sub-millimetre 
accuracy in previous validation studies.24,25 All the results 
of the cortical surface reconstruction were visually 
examined by PF and MEG, and manual interventions 
done mainly by placing control points at regions distorted 
by gross pathology. This step improves the quality of 
segmentation and regional parcellations of the entire 
brain, when needed. In all patients who had intracerebral 
haemorrhage, we used results from the unaﬀ ected 
hemisphere for all cortical and white matter measures, as 
previously described.9–11 Besides cortical thickness, the 
hippocampal volume and estimated total intracranial 
volumes were calculated again from FreeSurfer 
parcellations.26,27 The estimated total intracranial volume 
represents the volume within the cranium and allows 
correction for head size variation within the population 
examined. Hippocampal volumes were expressed as a 
percent of estimated total intracranial volume.
Two other measures of CAA-related structural injury 
were examined: the total number of lobar microbleeds 
and the white matter hyperintensity volume. The number 
of lobar microbleeds was counted on a high resolution 
susceptibility-weighted MRI, based on previously 
published guidelines.28 White matter hyperintensity 
volume was calculated with a home-made, semiautomated 
algorithm that produced maps of white matter 
hyperintensity.11 All the maps generated by this algorithm 
were visually checked to verify their accuracy, manually 
corrected when needed and the white matter 
hyperintensity volume was expressed as a percentage of 
estimated total intracranial volume.
The BOLD time-to-peak (in seconds), a physiological 
marker of vascular reactivity, was calculated from the 
fMRI acquisitions as described.9
Statistical analysis
The primary objective of the study was to compare cortical 
thickness between individuals with CAA and healthy 
controls; the overarching hypothesis was that CAA 
pathology causes cortical atrophy. Bivariate analyses were 
done with the χ² test for ratios, and the t test for 
continuous variables. Bivariate correlation analyses were 
done to test the association between continuous variables 
and Spearman’s ρ for variables that did not have a normal 
distribution. Multivariate linear regression models were 
built to test the association between diagnosis of CAA and 
cortical thinning, after adjustment for covariates. These 
covariates were identiﬁ ed based on the results of bivariate 
analyses in this study and previous reports, and included 
age, sex, white matter hyperintensity volume, and ﬁ nally 
hippocampal volume as a surrogate for parenchymal 
amyloid-related damage. Separate multi variate models 
were built and reported for each group comparison—ie, 
sporadic CAA and its comparator cohorts (two control 
groups and patients with Alzheimer’s disease), as well as 
HCHWA-D and respective controls. Additional multi-
variable models were done omitting patients with 
sporadic CAA and intracerebral haemorrhage, to exclude 
confounding from these lesions. Because lobar micro-
bleeds are part of the presentation and diagnostic criteria 
for CAA, we used multivariate models restricted to the 
CAA cohorts to test for their association with cortical 
thickness. When regression models incorporating all 
covariates risked overﬁ tting a model with a relatively 
Thinner in CAA Thicker in CAA
p value
Lateral
Medial
Hereditary CAA
Controls
L R
L R
10–5 0·01 0·01 10–5
Figure 1: Diﬀ erences in cortical thickness between patients with hereditary cerebral haemorrhage with 
amyloidosis–Dutch type and their age-matched controls
A general linear model was computed to schematically explore the regional diﬀ erences in cortical thickness between 
patients with HCHWA-D and healthy controls, after adjusting for age and sex. Topographic surface maps were 
generated using a threshold of p<0·01 (with false discovery rate correction for multiple comparisons). The resulting 
maps show the statistically signiﬁ cant regional diﬀ erences in cortical thickness. CAA=cerebral amyloid angiopathy. 
HCHWA-D=hereditary cerebral haemorrhage with amyloidosis–Dutch type.  L=left. R=right.
Patients with 
HCHWA-D (n=26)
Healthy controls 
(n=28)*
Mean diﬀ erence 
(95% CI)†
p value
Cortical thickness, mm 2·31 (0·18) 2·42 (0·10) –0·112 (–0·190 to –0·034) 0·006
Hippocampal volume, 
% of intracranial 
volume
0·54% (0·13) 0·58% (0·07) –0·04 (–0·10 to 0·01) 0·113
BOLD time-to-peak (s) 10·6 (8·5) 2·7 (3·2) 7·9 (4·4 to 11·4) <0·0001
Data are mean (SD) or diﬀ erence (95% CI). HCHWA-D=hereditary cerebral haemorrhage with amyloidosis–Dutch type. 
BOLD=blood-oxygen-level-dependent. *Healthy controls matched to the patients with HCHWA-D.†Mean diﬀ erence 
represents the diﬀ erence of this measure between HCHWA-D and the healthy control cohorts.
Table 2: Comparisons between patients with HCHWA-D and age-matched healthy controls
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small number of observations or false negatives due to 
multicollinearity, we applied backward elimination 
(p<0·10 for retention) to remove non-signiﬁ cant terms. 
Mediation analyses were done using methods of Baron 
and Kenny as well as the Sobel test.29,30 For the mediation 
analysis, the diagnosis (CAA vs healthy control) was 
used as the independent variable (potential eﬀ ector), 
time-to-peak of BOLD response as the potential mediator, 
and cortical thickness as the dependent variable. The 
Sobel test is useful to estimate the percentage of the total 
eﬀ ect that is mediated and the results of both approaches 
were reported. A two-tailed threshold for signiﬁ cance of 
p<0·05 was used.
A general linear model was computed to schematically 
explore the regional diﬀ erences in cortical thickness 
between patients with CAA and healthy controls, after 
adjusting for age and sex. Topographic surface maps 
were generated using a threshold of p<0·01 (with false 
discovery rate correction for multiple comparisons). The 
resulting maps show the statistically signiﬁ cant regional 
diﬀ erences in cortical thickness between the CAA and 
their age-matched healthy control cohorts.
All statistical analyses were done with SPSS software 
(version 23).
Role of the funding source
The funding source of the study had no role in the 
performance of this study, analyses, interpretation of 
results, or manuscript preparation. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Table 1 shows the characteristics of the cohorts included in 
our study. Patients with HCHWA-D (n=26) and their 
respective controls (n=28) were of similar ages (p=0·624; 
table 1). Patients with HCHWA-D had thinner cortices 
than controls (2·31 mm [SD 0·18] vs 2·42 (0·10), p=0·006; 
table 2, ﬁ gure 1). Hippocampal volume did not signiﬁ cantly 
diﬀ er between HCHWA-D and controls (p=0·11; table 2). 
A multivariate linear regression model was built to test 
the association between diagnosis of HCHWA-D and 
cortical thinning, after adjustment for covariates that 
included age, sex, white matter hyperintensity volume, 
and ﬁ nally hippocampal volume as a surrogate for 
parenchymal amyloid-related damage. The diagnosis of 
HCHWA-D was independently associated with lower 
cortical thickness (p=0·0002). Other variables 
independently associated with cortical thickness were age 
and hippocampal volume, but not white matter 
hyperintensity and sex (data not shown). Cortical thickness 
did not correlate with white matter hyperintensity or lobar 
microbleeds in a multivariate model adjusted for age 
within the HCHWA-D cohort (data not shown).
We tested the generalisability of these ﬁ ndings from a 
pure CAA cohort to the more common situation of 
sporadic CAA. We age-matched patients with sporadic 
CAA (n=63) with individuals from two healthy control 
cohorts (HAB, n=126; and ADNI, n=63), and patients 
with Alzheimer’s disease (ADNI, n=63; table 1); the 
mean age of individuals in this cohort was 72·3 years 
(SD 5·4). The results of comparisons between CAA and 
these contrast groups are given in table 3. Fewer patients 
with sporadic CAA were women than in either healthy 
control group (table 1), so we therefore entered sex in all 
multivariate models.
Patients with CAA presented with signiﬁ cantly lower 
global cortical thickness (2·17 mm [SD 0·11]) when 
compared with both healthy control cohorts (both 
p<0·0001; table 3). These diﬀ erences were most 
pronounced in the occipital, temporal, posterior parietal, 
Patients with 
sporadic CAA; 
outcome 
measures
ADNI healthy controls* HAB healthy controls* ADNI patients with Alzheimer’s disease
Outcome 
measures
Mean diﬀ erence versus 
CAA (95% CI; p value)†
Outcome 
measures
Mean diﬀ erence versus CAA 
(95% CI; p value)†
Outcome 
measures
Mean diﬀ erence versus CAA 
(95% CI; p value)†
All individuals
Number of individuals 63 63 ·· 126 ·· 63 ··
Cortical thickness, mm 2·17 (0·11) 2·31 (0·07) –0·14 (–0·17 to –0·10; 
<0·0001)
2·27 (0·09) –0·10 (–0·13 to –0·06; <0·0001) 2·10 (0·14) 0·07 (0·11 to 0·02; 0·005)
Hippocampal volume, 
% of intracranial volume
0·41% (0·07) 0·49 (0·07) –0·08 (–0·11 to –0·06; 
<0·0001)
0·51 (0·07) –0·10 (–0·12 to –0·08; <0·0001) 0·36% (0·08) 0·05 (0·07 to 0·02; <0·0001)
Excluding intracerebral haemorrhage‡
Number of individuals 32 32 ·· 64 ·· ·· ··
Cortical thickness, mm 2·16 (0·12) 2·29 (0·08) –0·13 (–0·18 to –0·08; 
<0·0001)
2·27 (0·08) –0·11 (–0·15 to –0·06; <0·0001) ·· ··
Data are n, mean (SD), or mean diﬀ erence (95% CI; p value). CAA=cerebral amyloid angiopathy. HAB=Harvard Aging Brain. ADNI=Alzheimer’s Disease Neuroimaging Initiative. *Healthy controls age-matched to 
the patients with sporadic CAA. †Mean diﬀ erence represents the diﬀ erence between sporadic CAA and the particular cohort. ‡Analysis after exclusion of 31 patients with CAA who had intracerebral haemorrhage, 
and their matched controls. 
Table 3: Comparisons between patients with sporadic CAA and controls (healthy individuals or those with Alzheimer’s disease)
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and medial frontal regions (ﬁ gure 2). We repeated these 
comparisons after excluding 31 patients with CAA who 
had intracerebral haemorrhage (and their matched 
healthy controls), to overcome any potential confounding 
eﬀ ect of these lesions. The remaining 32 patients with 
CAA without intracerebral haemorrhage again had 
signiﬁ cantly lower cortical thickness (2·16 mm [SD 0·12]) 
versus both healthy control groups (both p<0·0001; 
table 3). The diagnosis of CAA was independently 
associated with cortical thinning compared with both 
healthy control groups after adjustment for the covariates 
above (p=0·007). Similar results were obtained when the 
multivariate models were limited to CAA patients 
without intracerebral haemorrhage and corresponding 
healthy controls (p=0·010). There was again no 
association between cortical thickness and total number 
of lobar microbleeds or white matter hyperintensity 
volume after controlling for age within the sporadic CAA 
cohort (data not shown).
The patients with Alzheimer’s disease were in the early 
stages of this disease: 36 (57%) had a clinical dementia 
rating of 0·5 (normal rating 0, abnormal range 0·5–3) 
and 27 (43%) had a clinical dementia rating of 1. Patients 
with Alzheimer’s disease showed signiﬁ cantly thinner 
cortices when compared with both the CAA (table 3) and 
healthy control groups (ADNI healthy vs Alzheimer’s 
disease, mean diﬀ erence –0·20 [95% CI –0·24 to –0·16], 
p<0·0001; HAB healthy vs Alzheimer’s disease –0·16 
[–0·20 to –0·13], p<0·0001). Hippocampal volume was 
signiﬁ cantly reduced in CAA (table 3) versus both healthy 
control cohorts (both p<0·0001), and was smaller in the 
Alzheimer’s disease than in CAA (mean diﬀ erence –0·05 
[95% CI –0·07 to –0·02], p=0·001).
BOLD time-to-peak, a functional marker of vascular 
reactivity thought to mediate ischaemic injury in CAA,9,12 
was signiﬁ cantly longer in patients with HCHWA-D than 
in controls (p<0·0001; table 2). Prolonged BOLD time-to-
peak correlated with decreased cortical thickness within 
the HCHWA-D cohort (ρ=–0·58, p=0·003), but not in the 
age-matched healthy control group (ρ=0·05, p=0·810). 
Within the HCHWA-D cohort, BOLD time-to-peak 
remained independently correlated with cortical thickness 
after adjustment for age, sex, white matter hyperintensity 
volume, microbleed count, hippocampal volume, and 
presence of intracerebral haemorrhage (p=0·028). In 
patients with sporadic CAA, cortical thickness was also 
negatively correlated with BOLD time-to-peak (r=–0·4, 
p=0·015) and remained signiﬁ cant after adjusting for the 
above covariates (p=0·007). We did mediation analyses29,30 
to address whether some of the eﬀ ect of HCHWA-D on 
cortical thickness is mediated by vascular dysfunction as 
measured by prolonged BOLD time-to-peak. There was a 
signiﬁ cant initial relationship between the diagnosis of 
HCHWA-D and cortical thickness (β=0·22, p=0·01) that 
was non-signiﬁ cant after controlling for BOLD time-to-
peak (β=0·12, p=0·2), indicating that BOLD time-to-peak 
might mediate the relationship between HCHWA-D 
diagnosis and cortical thickness. The Sobel test also found 
BOLD time-to-peak (t=2·4, p=0·018) to be a signiﬁ cant 
mediator of the inﬂ uence of HCHWA-D on cortical 
thickness, explaining 63% of the total eﬀ ect.
Discussion
To identify the contribution of cerebrovascular amyloid 
pathology to cortical atrophy, we evaluated cortical 
thickness in patients with a monogenic form of CAA 
largely devoid of parenchymal Alzheimer’s disease 
pathology, as well as in patients with sporadic CAA 
without dementia. Both hereditary and sporadic CAA 
groups showed signiﬁ cant decreases in cortical thickness 
(5–6%) when compared with age-matched healthy 
controls, whereas patients with Alzheimer’s disease 
exhibited even greater cortical thinning (3%) than age-
matched patients with sporadic CAA.
Cortical atrophy in CAA could be related to several 
factors: confounding from concomitant parenchymal 
Alzheimer’s disease pathology; cortical eﬀ ects of CAA-
related structural lesions; or CAA-related vascular 
dysfunction. We addressed the ﬁ rst possibility by 
minimising the confounding of Alzheimer’s disease 
pathology through the unique opportunity aﬀ orded in 
patients with HCHWA-D, and noted essentially the same 
extent and pattern of cortical thinning as in the cohort of 
sporadic CAA. Our results further showed no major 
eﬀ ects on cortical thickness of structural lesions, such as 
Thinner in CAA Thicker in CAA
p value
Lateral
Medial
Sporadic CAA
Controls
L R
L R
10–6 0·004 0·004 10–6
Figure 2: Diﬀ erences in cortical thickness between patients with sporadic cerebral amyloid angiopathy and 
their age-matched controls
A general linear model was computed to schematically explore the regional diﬀ erences in cortical thickness 
between patients with sporadic CAA and healthy controls, after adjusting for age and sex. Topographic surface 
maps were generated using a threshold of p<0·01 (with false discovery rate correction for multiple comparisons). 
The resulting maps show the statistically signiﬁ cant regional diﬀ erences in cortical thickness. CAA=cerebral 
amyloid angiopathy. L=left. R=right.
Articles
www.thelancet.com/neurology   Vol 15   July 2016 817
lobar microbleed or white matter hyperintensity, and 
suggest instead that vascular dysfunction may at least 
partly mediate CAA-related cortical damage.
A strength of our study was inclusion of patients with 
HCHWA-D and age-matched controls identiﬁ ed and 
scanned at a single site. The codon 693 mutation of the 
amyloid precursor protein gene APP15 causes extensive 
amyloid deposition in the walls of meningocortical 
arterioles, minimal parenchymal Aβ deposition in the 
form of so-called diﬀ use plaques, and essentially no 
dense core plaque or tau deposition.31 We found decreased 
cortical thickness in this essentially pure phenotype of 
CAA in relatively young patients (mean age 46 years) and 
no association between cortical thickness and structural 
lesions. We have replicated these results in patients with 
the more prevalent condition of sporadic CAA. Adding 
hippocampal volume (a commonly used diagnostic 
biomarker in Alzheimer’s disease) as a covariate in 
multivariate regression models did not change the 
independent association between CAA and global cortical 
thinning, further supporting our hypothesis that vascular 
amyloid directly contributes to cortical atrophy.
Cortical atrophy could be related to any of the various 
CAA pathology-related lesions: intracerebral haemorrhage, 
microbleeds, cortical microinfarcts, and even white matter 
lesions through local or dying-back mechanisms. As in 
previous studies,9,11 we collected data from the hemisphere 
that was not aﬀ ected by intracerebral haemorrhage, and 
repetition of all pertinent analyses in the subgroup of 
patients without intracerebral haemorrhage did not 
change the results. Lobar microbleed counts and white 
matter hyperintensity volumes did not correlate with 
cortical thickness in either CAA cohort in multivariate 
models, similar to ﬁ ndings reported previously for another 
small vessel disease, cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leuco-
encephalopathy.32 Future studies designed to detect 
cortical microinfarcts and measure the remote eﬀ ects of 
small deep lesions, such as lacunes, will increase our 
understanding of the mechanisms of cortical atrophy in 
patients with CAA.
Cortical thinning in CAA was noted in the occipital, 
temporal, posterior parietal, and medial frontal regions, 
areas previously reported to be particularly susceptible to 
vascular amyloid load by pathology and in-vivo amyloid 
imaging.6,33,34 Amyloid burden in the medial frontal region 
has also been identiﬁ ed as an independent predictor of 
future haemorrhages in patients with CAA.35 Although 
the distribution of cortical thinning in patients with CAA 
resembles the distribution of vascular amyloid, it also 
overlaps with the pattern of cortical thinning observed in 
Alzheimer’s disease, suggesting that these patterns may 
not be entirely disease speciﬁ c.36  We did not observe 
substantial qualitative diﬀ erences in the patterns of 
cortical thinning between the individuals with hereditary 
and those with sporadic CAA. Because of substantial age 
diﬀ erences between the two CAA cohorts (approximately 
25 years, with no age overlap) and the large eﬀ ect of age 
on cortical thickness, we could not quantitatively compare 
the pattern of cortical thinning between sporadic and 
hereditary CAA.
BOLD time-to-peak appears to be a marker of vascular 
dysfunction in patients with sporadic CAA and, on the 
basis of our data, also in the younger patients with 
HCHWA-D.9,12 There was a strong and independent 
negative correlation between BOLD time-to-peak and 
cortical thickness. Consequently, vascular dysfunction—
expressed as delay in haemodynamic response—might 
contribute to cortical thinning in patients with CAA. 
Cortical thinning did not correlate with BOLD time-to-
peak in the respective controls, supporting the conclusion 
that vascular amyloid, but not the cortical thickness itself, 
drives this association. Furthermore, both mediation 
analyses found that vascular dysfunction mediates a 
signiﬁ cant part of HCHWA-D’s eﬀ ect on cortical thinning. 
Some recent evidence also suggests reduced blood ﬂ ow 
and possibly cortical atrophy in patients with CAA: two 
studies showed grey matter loss and hypometabolism in 
the temporal lobe of patients with Alzheimer’s disease 
with microbleeds, when compared with Alzheimer’s 
disease without microbleeds, and widespread reductions 
in cortical perfusion in healthy octogenarians with 
cortical microbleeds (mean age 87·6 years [SD 2·8]), 
when compared with age-similar healthy controls without 
microbleeds (mean age 86·2 years [SD 2·5]).37,38
The lack of a dedicated control group for sporadic CAA 
is a weakness of the study. We note, however, essentially 
similar diﬀ erences in cortical measures in the two age-
matched control groups compared with the patients with 
sporadic CAA, supporting the robustness of the ﬁ ndings. 
Other notable weaknesses were the lack of fMRI in the 
ﬁ rst 26 patients with sporadic CAA enrolled early in the 
study and in the corresponding controls. We cannot 
exclude the possibility that the parenchymal Aβ that has 
been observed as diﬀ use plaques in patients with 
HCHWA-D might have some contribution to cortical 
thinning even in hereditary CAA.39 We also again note 
that, in the absence of a validated molecular tracer speciﬁ c 
to CAA or Alzheimer’s disease pathology, it is impossible 
to exclude some degree of confounding by concurrent 
parenchymal Alzheimer’s disease pathology on cortical 
thickness. Eﬀ orts to produce a speciﬁ c marker for CAA 
are underway. Short of such a speciﬁ c marker, we have 
analysed a series of neuroimaging markers that capture 
aspects of CAA severity—lobar microbleeds, white matter 
hyperintensity volume, vascular reactivity—and ﬁ nd 
correlation only with vascular reactivity, raising the 
possibility that this aspect of CAA severity contributes to 
the CAA-related reduction in cortical thickness. In all 
other respects, the ﬁ ndings from the sporadic CAA 
analyses replicated those from the less confounded 
HCHWA-D analyses, suggesting that the observed cortical 
thinning and association with vascular dysfunction are 
indeed driven by advanced CAA pathology.
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In conclusion, our ﬁ ndings show that cerebrovascular 
amyloid pathology is an independent contributor to 
cortical atrophy and suggest that this eﬀ ect is at least 
partly mediated by CAA-related vascular dysfunction. 
These results indicate that a relatively common cerebral 
small vessel disease results in cortical changes 
independent of its profound subcortical eﬀ ects. Our 
results also add support to the view that the contributory 
role of CAA pathology and small vessel diseases should 
be considered in eﬀ orts to reduce age-associated 
cognitive impairment.
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